Newsletter | January 23, 2023

01.23.23 -- The Status Of Adopting Continuous Manufacturing For Biologics

Featured Articles
Avoid Trade Secret Lawsuits In The Life Science Talent War

Life sciences companies can take a few proactive steps that may help limit the risk of trade secret claims when competing for talent in a tight labor market.

Why Partnerships Fuel Innovation

Innovation requires diversity of thought, dynamic conversation, adequate planning, and synergistic collaboration. Those qualities are must-haves for companies internally, but they are also essential when creating external partnerships.

A New Funding Model For A New Approach To Pain

The business model CEO Dr. Hernan Bazan and his colleagues put in place at South Rampart Pharma was not typical for a small biotech firm.

Web-Exclusive Content
Where Do We Stand On Adopting Continuous Manufacturing For Biologics?

Continuous manufacturing offers productivity and cost-saving benefits among other things, but technical and regulatory challenges have slowed uptake. Speeding up adoption will require innovation and knowledge sharing within the industry and regulatory support from the FDA.

Industry Insights
Taste Masking 101: Optimize Taste And Improve Patient Outcomes

Learn how swallowability and palatability play key factors related to patient acceptability and product development and about the variety of taste masking strategies including excipients, organoleptic and barrier coating approaches, and microencapsulation technologies.

Challenges Of Scaling Up Cell Therapy To New Geographies

Cell therapy has emerged as one of the most promising disruptive innovations in the pharma industry, but companies developing cell therapies have not been able to take full advantage of its massive potential.

Design Agile Manufacturing With An Integrated Drug Product Ecosystem

Companies wanting to accelerate biomanufacturing operations and use resources efficiently need access to technologies and solutions that can safely and efficiently complete workflow from idea to injection.

When To Outsource Protein Biologics Development And Manufacturing

Learn the elements and market factors impacting the make/build vs. buy decision, considerations to examine when evaluating options, and best practices for navigating this decision.

Digital Edition
January 2023 Digital Edition

Inside you will find more on:

  • Peter Marks Interview
  • White Collar Crime & Fraud
  • Clinical Trial Topics
  • Business Strategies

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director.